Document is current
Any future updates will be listed below
-
Authors
Martin Pérez, Carla https://orcid.org/0000-0002-9852-1976
Ruiz-Rius, Sílvia
Ramírez-Morros, Anna https://orcid.org/0000-0001-8263-1292
Vidal, Marta
Jiménez, Alfons https://orcid.org/0000-0003-0301-3344
Izquierdo, Luis https://orcid.org/0000-0002-3704-9874
Santamaria, Pere
Vidal-Alaball, Josep https://orcid.org/0000-0002-3527-4242
Beeson, James G.
Molinos-Albert, Luis M. https://orcid.org/0000-0001-5447-6803
Aguilar, Ruth https://orcid.org/0000-0003-3277-3107
Ruiz-Comellas, Anna https://orcid.org/0000-0002-2848-2326
Moncunill, Gemma https://orcid.org/0000-0001-5105-9836
Dobaño, Carlota https://orcid.org/0000-0002-6751-4060
- License Information
-
More Information
Article History
Received: 11 February 2026
Accepted: 3 June 2026
First Online: 24 June 2026
Competing interests
: P. Santamaria is founder, scientific officer and stock holder of Parvus Therapeutics and receives funding from the company. He also has a consulting agreement with Sanofi. Carlota Dobaño is an Editorial Board Member for Communications Medicine but was not involved in the editorial review or peer review, nor in the decision to publish this article. The other authors declare no competing interests.
